BACH MEDICAL GROUP INC. NPI 1902280019

NPI Details

BACH MEDICAL GROUP, INC. is an anatomic pathology and clinical pathology pathology in Irvine, CA. The provider is a pathologist deals with the causes and nature of disease and contributes to diagnosis, prognosis and treatment through knowledge gained by the laboratory application of the biologic, chemical and physical sciences. A pathologist uses information gathered from the microscopic examination of tissue specimens, cells and body fluids, and from clinical laboratory tests on body fluids and secretions for the diagnosis, exclusion and monitoring of disease. BACH MEDICAL GROUP, INC. NPI is 1902280019. The provider is registered as an organization entity type and is a multi-specialty group.
The provider Is Doing Business As Bach Diagnostics.

The provider's business location address is:

17672 COWAN
IRVINE, CA
ZIP 92614-027
Phone: (800) 544-4181
Fax: (949) 236-6646

The provider's authorized official is Dylan Bach .
The authorized official title is Medical Director and has the following contact phone number (714) 273-4991.

The CLIA number assigned to this NPI record is 05D2101629 - independent with a certificate type of Certificate of Compliance.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Detection test by nucleic acid for organism, amplified probe technique (HCPCS:87798)
• Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source (HCPCS:G2023)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within (HCPCS:U0005)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r (HCPCS:U0003)
• Special stained specimen slides to identify organisms including interpretation and report (HCPCS:88312)
• Preparation of tissue for examination by removing any calcium present (HCPCS:88311)
• Pathology examination of tissue using a microscope, intermediate complexity (HCPCS:88305)
• Detection test for candida species (yeast), amplified probe technique (HCPCS:87481)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0483)
• Testing for presence of drug, by chemistry analyzers (HCPCS:80307)
• Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique (HCPCS:87641)
• Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique (HCPCS:87500)
• Dna test for detection of 4 aspergillus species (HCPCS:0109U)
• Pathology examination of tissue using a microscope (HCPCS:88302)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0482)
• Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique (HCPCS:87651)
• Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique (HCPCS:87653)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0481)
• Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique (HCPCS:87640)
• Manual urinalysis test with examination using microscope, automated (HCPCS:81001)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0480)
• Measure of severe acute respiratory syndrome coronavirus 2 (covid-19) antibody (HCPCS:86769)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)

The enumeration date for this NPI number is 7/17/2015 and was last updated on 11/26/2024.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: